<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To characterise the role played by <z:chebi fb="40" ids="18243">dopamine</z:chebi> receptors in ischaemic brain damage, we have evaluated the effects of pergolide, <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> and <z:chebi fb="0" ids="51164">lisuride</z:chebi> (<z:chebi fb="40" ids="18243">dopamine</z:chebi> D2 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>), <z:chebi fb="6" ids="5613">haloperidol</z:chebi> (a <z:chebi fb="40" ids="18243">dopamine</z:chebi> D2 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>), 2,3,4,5-tetrahydro-7,8,dihydroxy-1-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-1H-3-<z:chebi fb="0" ids="35676">benzazepine</z:chebi> (SKF 38393; a <z:chebi fb="40" ids="18243">dopamine</z:chebi> D1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>) and (R)-(+)-8-chloro 2,3,4,5-tetra-hydro-3-<z:chebi fb="36" ids="29309">methyl</z:chebi>-5-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-1H-3-benzazepin-7-ol (SCH 23390; a <z:chebi fb="40" ids="18243">dopamine</z:chebi> D1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>) in the gerbil model of global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischaemia</z:e> was induced by 5 min of bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> under <z:chebi fb="2" ids="5615">halothane</z:chebi> anaesthesia </plain></SENT>
<SENT sid="2" pm="."><plain>Sham operated animals were used as controls </plain></SENT>
<SENT sid="3" pm="."><plain>Pergolide (0.5 or 1.0 mg/kg i.p), <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> (0.5 or 1.0 mg/kg i.p.), <z:chebi fb="0" ids="51164">lisuride</z:chebi> (0.5 or 1.0 mg/kg i.p.), SCH 23390 (0.1 or 1.0 mg/kg i.p.), <z:chebi fb="6" ids="5613">haloperidol</z:chebi> (0.5, 1.0 or 2 mg/kg i.p.) and SKF 38393 (1.0 or 2 mg/kg i.p.) were administered 1 h before occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Five-minute-occluded animals had extensive damage in the CA1 region of the hippocampus 5 days after surgery </plain></SENT>
<SENT sid="5" pm="."><plain>Pergolide 0.5 and 1.0 mg/kg i.p. provided significant (P &lt; 0.05 and P &lt; 0.01, respectively) neuroprotection against the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced hippocampal damage </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="3181">Bromocriptine</z:chebi> and <z:chebi fb="0" ids="51164">lisuride</z:chebi> also provided significant (P &lt; 0.05) neuroprotection, but only at the higher 1.0 mg/kg dose </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, the <z:chebi fb="40" ids="18243">dopamine</z:chebi> D2 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (<z:chebi fb="6" ids="5613">haloperidol</z:chebi>), the <z:chebi fb="40" ids="18243">dopamine</z:chebi> D1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> (SKF 38393) and the <z:chebi fb="40" ids="18243">dopamine</z:chebi> D1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (SCH 23390) failed to provide any neuroprotection in the model </plain></SENT>
<SENT sid="8" pm="."><plain>These results support studies indicating that <z:chebi fb="40" ids="18243">dopamine</z:chebi> is important in ischaemic situations </plain></SENT>
<SENT sid="9" pm="."><plain>The results also indicate that <z:chebi fb="40" ids="18243">dopamine</z:chebi> D2 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> are neuroprotective against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced brain injury and may play a role in <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> </plain></SENT>
</text></document>